References
- 1. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008 Mar 6;358(10):1037-52. DOI: 10.1056/NEJMra07275310.1056/NEJMra072753
- 2. National Clinical Guideline Centre (UK). Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing [Internet]. London: Royal College of Physicians (UK); 2012 Jun. http://www.ncbi.nlm.nih.gov/books/NBK132796/
- 3. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. 1996 Dec;17(12):1912.10.1093/oxfordjournals.eurheartj.a014812
- 4. Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, dit Sollier CB, et al.; FITENAT Study Group. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul Fibrinolysis. 2009 Oct;20(7):503-10. DOI: 10.1097/ MBC.0b013e32832f5d7a10.1097/MBC.0b013e32832f5d7a
- 5. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters, Thrombosis Research, 1993 April;70(2):123-25. DOI: 10.1016/0049-3848(93)90153-F10.1016/0049-3848(93)90153-F
- 6. Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova-Stojkova S, et al. Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol. 2008;55(3):587-94. Epub 2008 Sep 18.10.18388/abp.2008_3065
- 7. Quéré I, Chassé JF, Dupuy E, Bellet E, Molho-Sabatier P, Tobelem G, et al. Homocysteine, 5,10-methylenetetrahydrofolate reductase and deep venous thrombosis. Survey of 120 patients in internal medicine. Rev Med Interne. 1998 Jan;19(1):29-33. DOI: 10.1016/S0248-8663(97)83696-X10.1016/S0248-8663(97)83696-X
- 8. Simone B, Stefano VD, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013 Aug 1;28(8):621-47. DOI: 10.1007/s10654-013-9825-810.1007/s10654-013-9825-8393523723900608
- 9. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. DOI: 10.1038/gim.2012.16510.1038/gim.2012.16523288205
- 10. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost. 2013 Oct;110(4):697-705. DOI: 10.1160/TH13-01-001110.1160/TH13-01-001123846575
- 11. Ilhan E, Demirci D, Güvenç TS, Calık AN. Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. Turk Kardiyol Dern Ars. 2010 Jun;38(4):275-8.
- 12. Choi BG, McLaughlin MA. Why men’s hearts break: cardiovascular effects of sex steroids. Endocrinol Metab Clin North Am. 2007 Jun;36(2):365-77. DOI: 10.1016/j.ecl.2007.03.01110.1016/j.ecl.2007.03.01117543724
- 13. Glueck CJ, Goldenberg N, Budhani S, Lotner D, Abuchaibe C, Gowda M.et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res. 2011 Oct;158(4):225-34. DOI: 10.1016/j.trsl.2011.06.00310.1016/j.trsl.2011.06.00321925119
- 14. Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Labitue F, Riaz MK, et al. Testosterone, Thrombophil